Tuesday, November 24, 2020

Markets for LG Display Transparent OLED are expanding worldwide.


              LG Display’s transparent OLED panel is used for the window of a subway in China.

LG Display has expanded its “transparent OLED” business towards the Japanese market after it did so with the Chinese market.

Panasonic announced that it would begin selling 55-inch transparent OLED modules in Japan, Taiwan, Singapore, Australia, and New Zealand starting from this year. This OLED module is based on LG Display’s transparent OLED panel and is less than one centimeters in thickness.

“Panasonic’s module was developed to target B2B (Business to Business) digital signage market in its native country and the Asia-Pacific market.” said one industry official. “LG Display supplied transparent OLED panels that are the key to the module.”

Not only does Panasonic’s module maintains contrast ratio of video contents even in an environment where the intensity of illumination is strong, but it also assists in providing clear images and videos. Panasonic attached a dimming unit that electrically controls light transmittance on the back of the panel and applied a technology that switches the panel between transparent mode and shading mode.

For example, the shading mode that controls the light that passes through the back of the panel is activated by lowering the transmittance of the dimming unit in an environment where the intensity of illumination is strong.

Panasonic explained that there can be many uses with the module as it can be used in various places such as commercial facilities, transportation infrastructures, and public facilities. It also added that a large display screen can also be made by attaching many panels together.

“Development of communication infrastructures and diversification of contents are taking place rapidly,” said Panasonic. “We have decided to commercialize the module due to a rise in expectations towards transparent display that is able to display new images and videos.”

LG Display’s transparent OLED supply chain is expected to expand continuously as there are growing demands for transparent OLEDs globally.

It is reported that Xiaomi’s 55-inch transparent OLED TV, which is the first in the world, is also equipped with LG Display’s transparent OLED panel. It is likely that the same panel is used for Panasonic’s OLED module.

LG Display’s transparent OLED panels are also used for windows of subways in Beijing and Shenzhen. Disney plans to build a space for experimenting with transparent OLED panel within its establishment with LG Display.

Korea IT News.

Monday, November 23, 2020

SPACE: StarShip coming into our atmosphere, filmed from the ISS. Video.


According to Gina Maria Colvin Hill, who posted the above video on Youtube, Mia Schopen has captured several images of what appears to be a Starship (UFO) and it is  coming into our atmosphere as filmed from the ISS. The ship is coming in and it is not a camera reflection.

IMHO the starship arrived in our atmosphere coming out from some kind of portal. Who knows.

Every kind of UFO or extraterrestrial visits have been happening for thousands of years, but maybe they are intraterrestrials who live underneath or underwater or inside a volcano. Just guessing.

Gina has a wonderful youtube channel where you can find a long playlist of her experiences finding  UFO presence https://www.youtube.com/c/GinaMariaColvinHill555/about

Wednesday, November 18, 2020

SCIENCE: PFIZER/BIONTECH Primary efficacy analysis demonstrates BNT162b2 vaccine to be 95% effective against COVID-19. Press Release.



Wednesday, November 18, 2020 - 06:59am

  • Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group
  • Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults over 65 years of age was over 94%
  • Safety data milestone required by U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) has been achieved
  • Data demonstrate vaccine was well tolerated across all populations with over 43,000 participants enrolled; no serious safety concerns observed; the only Grade 3 adverse event greater than 2% in frequency was fatigue at 3.8% and headache at 2.0%
  • Companies plan to submit within days to the FDA for EUA and share data with other regulatory agencies around the globe
  • The companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021
  • Pfizer is confident in its vast experience, expertise and existing cold-chain infrastructure to distribute the vaccine around the world

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose. The first primary objective analysis is based on 170 cases of COVID-19, as specified in the study protocol, of which 162 cases of COVID-19 were observed in the placebo group versus 8 cases in the BNT162b2 group. Efficacy was consistent across age, gender, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005595/en/

There were 10 severe cases of COVID-19 observed in the trial, with nine of the cases occurring in the placebo group and one in the BNT162b2 vaccinated group.

To date, the Data Monitoring Committee for the study has not reported any serious safety concerns related to the vaccine. A review of unblinded reactogenicity data from the final analysis which consisted of a randomized subset of at least 8,000 participants 18 years and older in the phase 2/3 study demonstrates that the vaccine was well tolerated, with most solicited adverse events resolving shortly after vaccination. The only Grade 3 (severe) solicited adverse events greater than or equal to 2% in frequency after the first or second dose was fatigue at 3.8% and headache at 2.0% following dose 2. Consistent with earlier shared results, older adults tended to report fewer and milder solicited adverse events following vaccination.

In addition, the companies announced that the safety milestone required by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) has been achieved. Pfizer and BioNTech plan to submit a request within days to the FDA for an EUA based on the totality of safety and efficacy data collected to date, as well as manufacturing data relating to the quality and consistency of the vaccine. These data also will be submitted to other regulatory agencies around the world.

“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world.”

“We are grateful that the first global trial to reach the final efficacy analysis mark indicates that a high rate of protection against COVID-19 can be achieved very fast after the first 30 µg dose, underscoring the power of BNT162 in providing early protection,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These achievements highlight the potential of mRNA as a new drug class. Our objective from the very beginning was to design and develop a vaccine that would generate rapid and potent protection against COVID-19 with a benign tolerability profile across all ages. We believe we have achieved this with our vaccine candidate BNT162b2 in all age groups studied so far and look forward to sharing further details with the regulatory authorities. I want to thank all the devoted women and men who contributed to this historically unprecedented achievement. We will continue to work with our partners and governments around the world to prepare for global distribution in 2020 and beyond.”

The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds, and 41% of global and 45% of U.S. participants are 56-85 years of age. A breakdown of the diversity of clinical trial participants can be found here from approximately 150 clinical trials sites in United States, Germany, Turkey, South Africa, Brazil and Argentina. The trial will continue to collect efficacy and safety data in participants for an additional two years.

Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021. Four of Pfizer’s facilities are part of the manufacturing and supply chain; St. Louis, MO; Andover, MA; and Kalamazoo, MI in the U.S.; and Puurs in Belgium. BioNTech’s German sites will also be leveraged for global supply.

Pfizer is confident in its vast experience, expertise and existing cold-chain infrastructure to distribute the vaccine around the world. The companies have developed specially designed, temperature-controlled thermal shippers utilizing dry ice to maintain temperature conditions of -70°C±10°C. They can be used be as temporary storage units for 15 days by refilling with dry ice. Each shipper contains a GPS-enabled thermal sensor to track the location and temperature of each vaccine shipment across their pre-set routes leveraging Pfizer’s broad distribution network.

Pfizer and BioNTech plan to submit the efficacy and safety data from the study for peer-review in a scientific journal once analysis of the data is completed.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer NewsLinkedInYouTube and like us on Facebook at Facebook.com/Pfizer.


Monday, November 16, 2020

SCIENCE: MODERNA COVID-19 vaccine Phase 3 study met statistical criteria with an efficacy of 94.5%. Press Release.

Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study.

The first interim analysis included 95 participants with confirmed cases of COVID-19

Phase 3 study met statistical criteria with a vaccine efficacy of 94.5% (p <0.0001)

Moderna intends to submit for an Emergency Use Authorization (EUA) with U.S. FDA in the coming weeks and expects the EUA to be based on the final analysis of 151 cases and a median follow-up of more than 2 months.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 16, 2020-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the independent, NIH-appointed Data Safety Monitoring Board (DSMB) for the Phase 3 study of mRNA-1273, its vaccine candidate against COVID-19, has informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. This study, known as the COVE study enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.

The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5% (p <0.0001).

A secondary endpoint analyzed severe cases of COVID-19 and included 11 severe cases (as defined in the study protocol) in this first interim analysis. All 11 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group.

The 95 COVID-19 cases included 15 older adults (ages 65+) and 20 participants identifying as being from diverse communities (including 12 Hispanic or LatinX, 4 Black or African Americans, 3 Asian Americans and 1 multiracial).

The interim analysis included a concurrent review of the available Phase 3 COVE study safety data by the DSMB, which did not report any significant safety concerns. A review of solicited adverse events indicated that the vaccine was generally well tolerated. The majority of adverse events were mild or moderate in severity. Grade 3 (severe) events greater than or equal to 2% in frequency after the first dose included injection site pain (2.7%), and after the second dose included fatigue (9.7%), myalgia (8.9%), arthralgia (5.2%), headache (4.5%), pain (4.1%) and erythema/redness at the injection site (2.0%). These solicited adverse events were generally short-lived. These data are subject to change based on ongoing analysis of further Phase 3 COVE study data and final analysis.

Preliminary analysis suggests a broadly consistent safety and efficacy profile across all evaluated subgroups.

As more cases accrue leading up to the final analysis, the Company expects the point estimate for vaccine efficacy may change. The Company plans to submit data from the full Phase 3 COVE study to a peer-reviewed publication.

“This is a pivotal moment in the development of our COVID-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible. All along, we have known that each day matters. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” said Stéphane Bancel, Chief Executive Officer of Moderna. “This milestone is only possible because of the hard work and sacrifices of so many. I want to thank the thousands of participants in our Phase 1, Phase 2 and Phase 3 studies, and the staff at our clinical trial sites who have been on the front lines of the fight against the virus.

They are an inspiration to us all. I want to thank the NIH, particularly NIAID, for their scientific leadership including through years of foundational research on potential pandemic threats at the Vaccine Research Center that led to the discovery of the best way to make Spike protein antigens that are being used in our vaccine and others’. I want to thank our partners at BARDA and Operation Warp Speed who has been instrumental in accelerating our progress to this point. Finally, I want to thank the Moderna team, our suppliers and our partners, for their tireless work across research, development and manufacturing of the vaccine. We look forward to the next milestones of submitting for a EUA in the U.S., and regulatory filings in countries around the world, while we continue to collect data on the safety and efficacy of the vaccine in the COVE study. We remain committed to and focused on doing our part to help end the COVID-19 pandemic.”

Based on these interim safety and efficacy data, Moderna intends to submit for an Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) in the coming weeks and anticipates having the EUA informed by the final safety and efficacy data (with a median duration of at least 2 months). Moderna also plans to submit applications for authorizations to global regulatory agencies.

Moderna is working with the U.S. Centers for Disease Control and Prevention (CDC), Operation Warp Speed and McKesson (NYSE: MCK), a COVID-19 vaccine distributor contracted by the U.S. government, as well as global stakeholders to be prepared for the distribution of mRNA-1273, in the event that it receives a EUA and similar global authorizations. By the end of 2020, the Company expects to have approximately 20 million doses of mRNA-1273 ready to ship in the U.S. The The company remains on track to manufacture 500 million to 1 billion doses globally in 2021. On November 10, the American Medical Association (AMA) issued a Current Procedural Terminology (CPT) code to report vaccination with mRNA-1273 (code: 91301). Moderna recently announced further progress towards ensuring the distribution, storage, and handling of the vaccine can be done using existing infrastructure.

To learn more about Moderna’s work on mRNA-1273, visit www.modernatx.com/COVID19.

About the Phase 3 COVE Study

The Phase 3 COVE trial is a randomized, 1:1 placebo-controlled study testing mRNA-1273 at the 100 µg dose level in 30,000 participants in the U.S., ages 18 and older. The primary endpoint is the prevention of symptomatic COVID-19 disease. Key secondary endpoints include prevention of severe COVID-19 disease and prevention of infection by SARS-CoV-2. The trial will continue to accrue additional data relevant to safety and efficacy even after a EUA is submitted. The final estimates of vaccine efficacy for both primary and secondary endpoints will depend on the totality of data that will accumulate to inform the final analysis. Moderna worked closely with BARDA and the NIH, including NIAID’s COVID-19 Prevention Network (CoVPN), to conduct the Phase 3 COVE study under Operation Warp Speed. Moderna’s partner PPD (Nasdaq: PPD), a leading global contract research organization providing comprehensive, integrated drug development, laboratory, and lifecycle management services, has also been essential to the successful execution of the COVE study.

The Phase 3 COVE study was designed in collaboration with the FDA and NIH to evaluate Americans at risk of severe COVID-19 disease and completed enrollment of 30,000 participants ages 18 and older in the U.S. on October 22, including those at high risk of the severe complications of COVID-19 disease. The COVE study includes more than 7,000 Americans over the age of 65. It also includes more than 5,000 Americans who are under the age of 65 but have high-risk chronic diseases that put them at increased risk of severe COVID-19, such as diabetes, severe obesity, and cardiac disease. These medically high-risk groups represent 42% of the total participants in the Phase 3 COVE study. The study also included communities that have historically been under-represented in clinical research and have been disproportionately impacted by COVID-19. The study includes more than 11,000 participants from communities of color, representing 37% of the study population, which is similar to the diversity of the U.S. at large. This includes more than 6,000 participants who identify as Hispanic or LatinX, and more than 3,000 participants who identify as Black or African American.

About mRNA-1273

mRNA-1273 is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from NIAID’s Vaccine Research Center. The first clinical batch, which was funded by the Coalition for Epidemic Preparedness Innovations, was completed on February 7, 2020 and underwent analytical testing; it was shipped to the NIH on February 24, 42 days from sequence selection. The first participant in the NIAID-led Phase 1 study of mRNA-1273 was dosed on March 16, 63 days from sequence selection to Phase 1 study dosing. On May 12, the FDA granted mRNA-1273 Fast Track designation. On May 29, the first participants in each age cohort: adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300) were dosed in the Phase 2 study of mRNA-1273. On July 8, the Phase 2 study completed enrollment.

Results from the second interim analysis of the NIH-led Phase 1 study of mRNA-1273 in the 56-70 and 71+ age groups was published on September 29 in The New England Journal of Medicine. On July 28, results from a non-human primate preclinical viral challenge study evaluating mRNA-1273 were published in The New England Journal of MedicineOn July 14, an interim analysis of the original cohorts in the NIH-led Phase 1 study of mRNA-1273 was published in The New England Journal of Medicine. mRNA-1273 currently is not approved for use by any regulatory body.

BARDA is supporting the continued research and development of mRNA-1273 with $955 million in federal funding under Contract no. 75A50120C00034. BARDA is reimbursing Moderna for 100 percent of the allowable costs incurred by the Company for conducting the program described in the BARDA contract. The U.S. government has agreed to provide up to $1.525 billion to purchase a supply of mRNA-1273 under the U.S. Department of Defense Contract No. W911QY-20-C-0100.


Sunday, November 15, 2020

Hyundai with Genesis brand is planning to launch 2021 electric car models with the world´s first wireless charging technology.


                  Genesis’ electric vehicle JW (project name) was seen in South Korea last month 

Genesis brand ( a Hyundai subsidiary) is attempting to become the first in the global electric vehicle industry to incorporate wireless charging capability into its electric cars that will be launched in 2021.

This capability helps the charger to recognize the electric car and assists the car with parking and charging at the same time.

Genesis is incorporating P&C technology into its first electric vehicles “eG80” and “JW (project name)” that will be launched in 2021. P&C technology is a technology that is able to verify the user and have payments made automatically just by plugging in a charging cable from either a fast or superfast charging station. It removes the complicated procedure of using a credit card or a corresponding card in order to go through an authentication process. It also supports “car pay”.

Also, the company plans to provide the industry’s first wireless charging technology as an option. This technology was developed along with WiTricity that is a leader when it comes to wireless charging of electric vehicles.

Considering the current level of this technology, the technology will be able to provide a speed of 6 to 8 kWh.

Because wireless charging requires a separate construction at the charging station, it is only offered as an option for upper trims. However, because standardization of wireless charging is currently taking place in Europe and the United States, it is expected that the technology will only be available locally starting from the second half of 2021.

Genesis is also working on home chargers specifically for its electric vehicles. It plans to develop 7 kW and 11 kW chargers, and they are expected to be applied to the company’s unconventional design.

“Wireless charging, P&C, and exclusive home chargers will be at the core of Genesis’ strategy in targeting the global electric vehicle market.” said one industry official. “Because the company’s goal is to target the global market, it is focusing heavily on raising the level of competition of its products and technologies.”

Regarding these new technologies, Genesis plans to introduce “eG80” and “JW” in the second quarter of 2021 and launch them in order by the end of 2021. JW particularly is based on Hyundai Motor Group’s first electric vehicle platform “E-GMP”. It is expected to provide optimal driving performance and have a shockingly large interior space that has never been seen before in gasoline cars.

Genesis’ image as a leader in electrification will be vastly improved when the company’s electric vehicles with P&C technology are launched in 2021.

Hyundai Motor Group stated that it cannot disclose any detailed technology or feature of its new electric vehicles that have yet to be released in advance.

Hyundai Motor Group is attempting innovative technologies that even Tesla has yet to attempt through the Genesis brand.

Although some automotive manufacturers such as Porsche are conducting pilot tests on this technology in the United States, they have yet to reach a level of commercialization.

Samsung Electronics Galaxy Note 20 Ultra 5G Factory Unlocked Android Cell Phone, US Version, 128GB of Storage, Mobile Gaming Smartphone, Long-Lasting Battery, Mystic White.Reviews: 4.5/5 stars on amazon

Saturday, November 14, 2020

Samsung Galaxy S21 5G models specifications leaked.


Samsung Electronics is going to present on January 14th, 2021, 3 models of its upcoming line of Galaxy smartphones, the S21 Code name 01, S21+ Code name T2, and the S21 Ultra Codename P3, all of them 5G capable. The Qualcomm CPU Snapdragon 875 as the successor of the 865 is yet to be announced.

Only the S21 Ultra will support the S Pen, but will not have a dedicated slot in the smartphone for it.

On the chart below  you can see the complete list of specifications of the 3 devices:

Samsung Electronics Galaxy Note 20 Ultra 5G Factory Unlocked Android Cell Phone, US Version, 128GB of Storage, Mobile Gaming Smartphone, Long-Lasting Battery, Mystic White on amazon  4.5/5 stars

Thursday, November 12, 2020

3Q 2020: Samsung is top smartphone vendor in the USA.

According to a recent report from Strategic Analytics, Samsung is the number one smartphone vendor in the US market, beating Apple iPhone for the first time in  3 years.

Samsung 33.7%

Apple      30.2%

LG           14.7%

This is the first time since the second quarter of 2017 that Samsung topped the U.S. smartphone market.

Solid sales of its mid-tier and budget smartphones, along with the launch of flagship devices, like the Galaxy Note 20 and Galaxy Z Fold2, apparently boosted Samsung's presence in the U.S.

The late launch of Apple's iPhone 12 series which began to sell from October. may have also helped Samsung to thrive in the U.S.

Samsung was also the leading vendor in the global smartphone market in the third quarter of the year with a 21.9 percent share, beating China brands Huawei Technologies Co. with a 14.1 percent share and Xiaomi Corp. with a 12.7 percent share. Apple had an 11.9 percent market share in the global market in the third quarter.


Markets for LG Display Transparent OLED are expanding worldwide.

                LG Display’s transparent OLED panel is used for the window of a subway in China. LG Display has expanded its “transparent OL...

Popular Posts